Working… Menu

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00814879
Recruitment Status : Completed
First Posted : December 25, 2008
Results First Posted : February 4, 2016
Last Update Posted : February 4, 2016
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Yale University

Brief Summary:
This pilot study will provide data on the safety and efficacy of the combination of Raltegravir (RAL) 400mg BID + Atazanavir (ATV) 300 mg BID in Antiretroviral (ARV)-experienced subjects that have a suppressed HIV viral load on a Ritonavir (RTV) boosted Protease Inhibitor (PI) based regimen who are then switched to a regimen of RAL 400mg BID +ATV 300mg BID.

Condition or disease Intervention/treatment Phase
Acquired Immune Deficiency Syndrome AIDS Human Immunodeficiency Virus HIV Infections Drug: Raltegravir Drug: Atazanavir Other: Standard treatment regimen Not Applicable

Detailed Description:

The purpose of this pilot study is to compare the virological efficacy, as measured by the proportion of patients with plasma HIV-RNA below the limit of detection (<50 copies/mL), of two ARV regimens; patients are randomized to remain on regimens containing N(t)RTI(s) + PI/r or switch to Raltegravir + ATV but without N(t)RTI(s).

Study Arms:

  1. N(t)RTI(s) based backbone + PI/r
  2. Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID

Antiretroviral (ARV) treatment guidelines currently recommend ARV regimens containing a Nucleos(t)ide Reverse Transcriptase Inhibitors [N(t)RTI(s)] based backbone with a Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI) or ritonavir boosted Protease Inhibitor (PI/r).(1) However, significant toxicity has been associated with N(t)RTI(s) and PI/r containing regimens. N(t)RTI(s) can cause lipoatrophy, lipid elevations, renal toxicity, neuropathy and lactic acidosis.(1) These toxicities have required clinicians and HIV-infected individuals to use alternative ARV regimens that do not use N(t)RTI(s). PIs are known to cause gastrointestinal side effects, dyslipidemia, and fat maldistribution (lipodystrophy).(1) The DHHS HIV treatment guidelines recommend that PIs should be given with a low dose of ritonavir (RTV). RTV is a PI that has an inhibitory effect on cytochrome P-450 3A4 isoenzyme which metabolizes most PIs. The addition of RTV serves as a pharmacokinetic "booster" by increasing PI drug concentrations.(1) However, RTV is known to increase PI side effects, elevate lipid levels and has significant drug-drug interactions with many medications given to HIV+ individuals.(1) These RTV drug interactions can complicate the medical care of an HIV-infected individual.

Raltegravir (RAL) is a recently FDA approved antiretroviral agent that inhibits HIV replication by blocking the integration of HIV proviral DNA into the host cell chromosomal DNA. RAL does not exhibit cross resistance to other ARV classes and thus has been initially used in HIV-infected individuals that are infected with drug resistant HIV strains. Recently published data on the use of RAL(2,3)in HIV-infected subjects with known ARV drug resistance or those without ARV drug resistance4 demonstrates that RAL is a potent agent, suppressing HIV viral loads in the majority of subjects and having excellent CD4 cell responses.(2-4) RAL is metabolized through glucuronidation by the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1) enzyme pathway.(5)ATV is a known inhibitor of this enzyme pathway. ATV will increase RAL levels,(5) however, the current DHHS HIV treatment guidelines do not recommend a change in the dose of RAL if given with ATV as persons receiving ATV and RAL have demonstrated good tolerability of the combination and low side effect profiles.(1-3,5)

The availability of RAL provides an opportunity to examine alternative ARV strategies that may be equally efficacious and less toxic than those currently recommended in HIV treatment guidelines. Such combinations might include RAL+ATV regimen without a concomitant N(t)RTI(s) based backbone and/or the inclusion of RTV. However, there is little data available to date regarding such a combination. HIV care providers have already begun to use the combination of RAL+ unboosted ATV as the patients they care for are intolerant of RTV or have had major side effects/toxicity with N(t)NRTIs. More investigation is required to determine if RAL+ATV is an efficacious and safe alternative to RTV boosted PI based ARV strategies. Before a RAL based strategy that does not include N(t)RTIs or RTV can be compared to other ARV class strategies for long-term efficacy outcomes, preliminary data on a RAL+ATV based regimen is needed. This pilot study will provide data on the safety and efficacy of the combination of RAL 400mg BID + ATV 300 mg BID in ARV-experienced subjects that have a suppressed HIV viral load on a RTV boosted PI based regimen who are then switched to a regimen of RAL 400mg BID +ATV 300mg BID.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Randomized, Open-Label Study Comparing the Safety and Efficacy of a Raltegravir Based NRTI Sparing Regimen
Study Start Date : May 2009
Actual Primary Completion Date : May 2013
Actual Study Completion Date : November 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Active Comparator: a.
N(t)RTI(s) based backbone & PI/r
Other: Standard treatment regimen
N(t)RTI(s) based backbone plus ritonavir boosted PI

Experimental: b.
Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID
Drug: Raltegravir
400 mg BID
Other Name: Isentress

Drug: Atazanavir
300 mg BID
Other Name: Reyataz

Primary Outcome Measures :
  1. Number of Patients Reaching Virologic Failure at Week 48. [ Time Frame: 48 Weeks ]
    Virologic failure was defined by protocol as a plasma HIV RNA >50 c/mL on 2 consecutive occasions >7 days apart or > 10 000 c/mL on one occasion (in the absence of an intercurrent infection or recent immunization).

Secondary Outcome Measures :
  1. Number of Patients With < 400 Copies HIV RNA/mL at Week 48 [ Time Frame: 48 weeks ]
  2. CD4+ Cell Count [ Time Frame: Weeks 24 ]
  3. CD4+ Cell Count [ Time Frame: Week 48 ]
  4. Cholesterol [ Time Frame: baseline, week 24, week 48 ]
    Total cholersterol (mg/dL)

  5. Mean Change in Total Bilirubin (mg/dL) From Baseline [ Time Frame: baseline and 48 weeks ]
    mean change in total bilirubin from baseline

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HIV-1 positive
  • On stable ARV-therapy for a minimum of 4 months with a HIV viral load of < 50 copies
  • Currently on a N(t)RTI(s) based backbone + PI/r
  • No prior history of PI drug resistance (by historical genotype or phenotype)
  • Aged > 18 years of age
  • Written informed consent
  • Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the last dose of investigational product, in such a manner that the risk of pregnancy is minimized.

Exclusion Criteria:

  • Prior exposure to Raltegravir or Elvitegravir
  • A detectable HIV viral load >50 copies within the last 4 months
  • An ARV change within the last 4 months
  • History of PI drug resistance
  • Prior virologic failure on an ATV containing regimen
  • Prior history of intolerance to ATV
  • Pregnant or nursing mothers
  • Pre-existing grade 3 or above laboratory toxicity except for lipids:
  • Absolute neutrophil count (ANC) < 750 cells/mL.
  • Hemoglobin < 8.0 g/dL.
  • Platelet count < 50 000 cells/mL.
  • AST, ALT and alkaline phosphatase > 5 x ULN.
  • Serum bilirubin > 5 x ULN.
  • calculated creatinine clearance of <50mL/min/1.73m2
  • Patients with chronic active hepatitis B infection defined by positive serum Hbs antigen
  • Use of any prohibited medications and/or the use of proton pump inhibitors in ATV plus RAL containing regimens)
  • Patients with current alcohol or illicit substance use that in judgment of investigator makes study adherence unlikely

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00814879

Layout table for location information
United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06504
Saint Raphael Healthcare System
New Haven, Connecticut, United States, 06511
Waterbury Hospital
Waterbury, Connecticut, United States, 06721
VA CT Healthcare Systems
West Haven, Connecticut, United States, 06516
United States, Florida
Comprehensive Care Center, Inc (dba Community AIDS Network)
Sarasota, Florida, United States, 34237
Sponsors and Collaborators
Yale University
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.
Layout table for investigator information
Principal Investigator: Michael J Kozal, MD Yale University
Layout table for additonal information
Responsible Party: Yale University Identifier: NCT00814879    
Other Study ID Numbers: 0811004448
Yale-No Nukes
First Posted: December 25, 2008    Key Record Dates
Results First Posted: February 4, 2016
Last Update Posted: February 4, 2016
Last Verified: January 2016
Keywords provided by Yale University:
Acquired Immune Deficiency Syndrome
Anti-Infective Agents
Antiviral Agents
Human Immunodeficiency Virus
HIV Protease Inhibitors
Nucleoside Reverse Transcriptase Inhibitors
treatment experienced
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Acquired Immunodeficiency Syndrome
Immunologic Deficiency Syndromes
Blood-Borne Infections
Communicable Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Immune System Diseases
Slow Virus Diseases
Raltegravir Potassium
Atazanavir Sulfate
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
HIV Integrase Inhibitors
Integrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
HIV Protease Inhibitors
Viral Protease Inhibitors
Protease Inhibitors